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Abstract Leptin concentrations are elevated in the majority of
obese individuals raising the possibility that leptin resistance
contributes to their obesity. Peripheral leptin administration for
48 h caused a several-fold increase in mRNA encoding the
suppressors of cytokine signaling SOCS-3 and CIS in hypotha-
lamus and peripheral tissues. Paradoxically, CIS and SOCS-3
mRNAs are also elevated in the leptin-deficient ob/ob mouse.
Forced expression of CIS in insulinoma cells prevented
transactivation mediated by leptin. Thus tissues continuously
exposed to leptin and/or other factors associated with obesity
accumulate excessive amounts of SOCS-3 and CIS which could
provide a potential mechanism for leptin resistance.
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1. Introduction
Leptin and leptin receptor (OB-R) de¢ciencies result in pro-
found obesity and endocrine dysfunction [1^3]. However, mu-
tations in the leptin system are rarely the cause of obesity in
humans. Instead, a parallel elevation of leptin levels with in-
creased obesity is observed in most rodent obesity models and
obese humans, raising the possibility that resistance to the
action of leptin contributes to their obesity [4,5]. Resistance
to exogenous leptin has been established in diet-induced ro-
dent obesity which is a model that resembles human obesity
[6,7]. Although the causes and mechanism(s) of leptin resist-
ance have not yet been de¢ned, high leptin concentrations
could have detrimental e¡ects on leptin receptor number or
on a signaling molecule.
The OB-R is closely related to the class I cytokine receptor
family, which includes for instance the granulocyte colony-
stimulating factor and gp130, the common signal transducing
chain of the receptors for interleukin 6 and leukemia inhib-
itory factor [1,2]. These receptors contain sequence motifs that
are required for interaction with the Janus kinases (JAKs) and
signal transducers and activators of transcription (STATs).
STAT proteins are recruited to the activated receptor-JAK
complex through Src-homology domains (SH2, SH3) and
are activated by tyrosine phosphorylation. In a number of
in vitro and in vivo studies, leptin has been shown to activate
the JAK/STAT signal transduction cascade [8^10]. Thus, lep-
tin activates a STAT-3-dependent satiety mechanism in the
mouse hypothalamus [8], STAT-3 in rat isolated pancreatic
islets [9] and STAT-5 in small intestine epithelium [10]. Lep-
tin-mediated STAT-3 and STAT-5 signaling in native islets
and small intestine has been corroborated by nuclear activa-
tion of STAT-3 in clonal insulin-secreting cells and activation
of STAT-5 in CACO-2 cells which are a human model of
small intestine epithelium [9,10]. Finally, leptin has been
found to modulate insulin action in hepatic cells by a¡ecting
activities of the insulin receptor substrate 1 (IRS-1) and IRS-
1-associated phosphatidylinositol 3-kinase [11].
Some of the immediate-early genes induced by the STAT
factors encode the suppressors of cytokine signaling (SOCS)
and cytokine-inducible SH2-containing protein (CIS) [12,13],
which regulate the intensity and duration of cytokine signal
transduction. The SOCS and CIS contain SH2 domains that
can mask phosphotyrosine residues on the cytokine receptor
and/or the catalytic region of JAK thus preventing activation
of the STAT proteins [12,13]. Acute (2 h) leptin treatment has
been shown to stimulate expression of SOCS-3 in hypothal-
amus of the ob/ob mouse and forced expression of SOCS-3
prevented leptin-mediated signal transduction [14]. In the
present study we determined the e¡ect of leptin treatment
for 48 h on the expression of key molecules involved in the
leptin system of lean and obese (ob/ob) mice. Leptin had no
e¡ect on the OB-R, STAT-3, STAT-5, SOCS-1 and SOCS-2
mRNA levels. In contrast, leptin treatment induced SOCS-3
and CIS mRNA by two to nine-fold in many target tissues for
leptin. Forced expression of CIS in clonal insulin-secreting
cells, prevented transcriptional activation of STAT-3-depend-
ent reporter constructs by leptin. Thus tissues exposed to rel-
atively high levels of leptin, as found in states of obesity,
accumulate excessive amounts of the suppressors of leptin
signaling, SOCS-3 and CIS, which could be a potential mech-
anism for leptin resistance.
2. Materials and methods
2.1. Synthesis, puri¢cation and characterisation of leptin
Recombinant murine leptin was produced and puri¢ed in Escher-
ichia coli as described previously [15,16], except that the gene was
cloned without N-terminal tags and expressed from a T7 promoter
in the vector pBroc413. The recombinant leptin material was ascer-
tained to be endotoxin-free by the Limulus amoebocyte lysate test
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[15,16]. The purity was >95% and the material has been shown pre-
viously to inhibit food intake when given either centrally or periph-
erally [15].
2.2. Animals and treatment
Lean (+/?) and obese (ob/ob) mice, aged 5^6 weeks, were obtained
from Harlan Olac (UK) and housed in cages with metal grid £oors on
a 12:12 h light-dark cycle and given unrestricted access to water and
powdered RM1 maintenance diet. Mice were then injected intraper-
itoneally (i.p.) twice a day (08.00 and 17.00 h) with 1.5 mg/kg re-
combinant murine leptin or saline vehicle for 2 days. Food intake
(correcting for spillage) and body weight were measured daily at
08.00 h. Mice were killed on the morning following the fourth dose
of leptin or vehicle in the fed state by cervical dislocation prior to the
removal of the following tissues: whole brain, hypothalamus, liver,
white adipose tissue (WAT) and small intestine.
2.3. Messenger RNA analysis
Total RNA was isolated using Tri Reagent (Amersham) and iso-
propanol precipitation. The integrity and loading of the RNA was
studied by detection scanning of ribosomal RNA bands (28S and
18S) in agarose gels before and after treatment with RNase-free
DNase I (Gibco/BRL). Single stranded cDNA synthesis was per-
formed from approximately 2 Wg of total RNA using oligo(dT)15ÿ18
(Invitrogen) in a ¢rst-strand synthesis kit (Pharmacia Biotech).
mRNA expression was determined by PCR using the following primer
sequences: 5P-ATGGTCCTCTGCGTACAG-3P and 5P-TGACAAG-
CAGTT AGAGTC-3P to amplify a 440 bp DNA fragment of
SOCS-1 (GenBank U88325), 5P-ATGGTA GCACGCAACCAGG-
TG-3P and 5P-CTCCAGCAGCTCGAAAAGGCA-3P to amplify a
460 bp DNA fragment of SOCS-2 (GenBank U88327), 5P-CCATGA-
CCCTGCGGTGCCTGG-3P and 5P-GGAATTTATATTCTTCCAA-
GT-3P to amplify a 593 bp DNA fragment of SOCS-3 (GenBank
U88328), 5P-GGAGTGGTGGCTCCTGGCTCT-3P and 5P-GGTA-
ATTGCATGG CTGCTGCA-3P to amplify a 630 bp DNA fragment
of CIS (GenBank D31943), 5P-GCTG GATGAAAGGGGACTTG-3P
and 5P-GTGACTTCCATACGCAAACC-3P to amplify a 348 bp frag-
ment of OB-R (common to all isoforms) (GenBank U53144), 5P-CA-
GAAAGTGTCCTACAAGGGCG-3P and 5P-CGTTGTTAGACTC-
CTCCATGTTC-3P to amplify a 239 bp fragment of STAT-3 (K and
the L isoforms) (GenBank U06922), 5P-CATCACGGACATCATCT-
CAGC-3P and 5P-GACATGTTTCTGAAGTGGGCG-3P to amplify a
302 bp fragment common to STAT-5a and STAT-5b (GenBank
Z48538) and 5P-CTCTTTAATGTCACGCACGAT-3P and 5P-AGTG-
CTGTGGGTGTAGGTACT-3 were used to amplify 534 bp of L-
actin (GenBank J00691). PCR products were then cloned directly
into a PCR-TRAP cloning system (GeneHunter Corp., USA) and
the identity of PCR products con¢rmed by sequencing using Thermo-
Sequenase terminator cycle sequencing kit (Amersham Life Sciences,
UK). Quantitation of mRNA expression was performed by quantita-
tive RT-PCR and ethidium bromide staining as described previously
[10,17]. Thus cDNA samples were diluted serially then split equally
and used either for PCR ampli¢cation of the test cDNA and the
housekeeping L-actin cDNA at a ¢xed number of PCR cycles (35
cycles for a test cDNA and 30 cycles for L-actin). Bands in agarose
gels were quantitated by scanning laser densitometry and changes in
the intensity of test cDNA then normalised to the intensity of the L-
actin cDNA, in order to provide information on the relative changes
of tissue gene expression. Results are expressed as mean þ S.E.M. and
statistical signi¢cance assessed using Student’s unpaired t-test.
2.4. Cell culture and transient transfection
RINm5F cells were routinely cultured as described previously [18].
The reporter constructs used were chloramphenicol acetyl transferase
(CAT) containing four copies of the human FcQRI interferon Q acti-
vated sequence (GAS) 5P-AGCTTGAGATGTATTTCCCAGAAAA-
GA-3P, or four copies of the human ICAM-1 interferon response
element (IRE), 5P-AGCTTAGTTTCCGGGAAAGCAC-3P, or four
copies of the L-casein STAT binding site (L-CAS), 5P-AGCTTA-
GATTTCTAGGAATTCAAATCA-3P. STAT binding sites were
cloned into the thymidine kinase (TK)-CAT vector pBLCAT2
(pBL; pBluescript) using a method described previously [19]. pSG5-
mCIS contains the mouse CIS cDNA cloned into the pSG5 eucaryotic
expression vector (Stratagene). For transfection experiments, cells
were split 1:3 and 24 h later transfected with 10 Wg supercoiled plas-
mid DNA by the DEAE-dextran technique. For co-transfection ex-
periments, 12^18 Wg of plasmid DNA was used (10 Wg reporter and 2^
8 Wg pSG5-CIS). Transfected cells were incubated for 6 h at 37‡C.
Cells were then washed twice with PBS, and fresh medium was added.
24 h later cells were serum-starved for 16 h, after which the cells were
stimulated for 12 h with leptin (100 nM) or vehicle and subsequently
harvested for CAT assay.
3. Results and discussion
Leptin, produced predominantly by the adipose tissue, pro-
vides a negative feedback to the the hypothalamus, reducing
food intake and increasing energy expenditure [1]. Elevation
of leptin levels with increased obesity is observed in most
rodent obesity models and obese humans, raising the possibil-
ity that resistance to the action of leptin contributes to their
condition [4,5]. For instance, leptin expression and secretion is
increased by 10^20-fold in adipose tissue of obese mice rela-
tive to the lean littermates [20,21]. In the present study, we
determined the e¡ect of leptin treatment for 48 h on the ex-
pression of key molecules involved in the leptin system as well
as the e¡ect on food intake and body weight of lean and obese
(ob/ob) mice. The dose of leptin used, 1.5 mg/kg i.p. twice
daily, is a sub-maximal leptin concentration within the dose-
response range originally reported to show leptin-mediated
inhibition of food intake and activation of the JAK/STAT
signaling pathway [10,22,23]. Leptin reduced food intake in
lean mice over the 2 day treatment period by 26% (8.64 þ 0.22
in control vs 7.23 þ 0.41 in leptin-treated; n = 9, P6 0.05) and
in obese mice by 35% (8.41 þ 0.53 in control vs 5.50 þ 0.34 in
leptin-treated n = 9, P6 0.001). Following leptin treatment for
48 h, body weight was reduced in lean mice (weight change:
+1.37 þ 0.60 g in control vs 33.24 þ 0.40 g in leptin-treated;
Fig. 1. The e¡ect of 48 h leptin treatment (2U1.5 mg/kg i.p. twice per
day) on SOCS-3 mRNA levels in (a)whole brain, (b) hypothalamus,
(c) liver and (d) small intestine. Results are expressed as mean þ
S.E.M. and statistical signi¢cance assessed using Student’s unpaired
t-test. **P6 0.001, ***P6 0.0002 vs 0 leptin. 2P6 0.004, VP6 0.001
vs lean mice. PCR products are displayed together with the quantita-
tion of SOCS-3 mRNA relative to L-actin.
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n = 9, P6 0.001) and in the obese mice (weight change:
+0.84 þ 0.37 g in control vs 33.42 þ 0.70 g in leptin-treated;
n = 9, P6 0.001).
Leptin mediates its diverse biological e¡ects by activating
the JAK/STAT pathway through the OB-Rb receptor isoform
in both central and peripheral tissues [8^10]. Using quantita-
tive RT-PCR as described previously [17], we ¢nd that the
leptin treatment had no e¡ect on the OB-R (common to all
OB-R splice variants), STAT-3, STAT-5 and SOCS-2 mRNA
levels in whole brain, hypothalamus, small intestine, liver and
WAT of the lean or obese (ob/ob) mice as summarised in
Table 1. SOCS-1 was not detected by RT-PCR in any of these
tissues from either treated or untreated animals. OB-R
mRNA levels were increased by 1.3-fold (P6 0.04) in whole
brain and by 2-fold (P6 0.001) in hypothalamus of ob/ob
mice compared with the lean littermates (Table 1). Western
blot analysis using antibodies raised against the N-terminal
domain of the OB-R con¢rmed the results, showing no e¡ect
of chronic leptin treatment on OB-R mRNA levels (data not
shown).
The SOCS proteins are a family of negative regulators of
cytokine signal transduction [13]. Following the 48 h leptin
treatment, the SOCS-3 mRNA levels were increased by 6-fold
(P6 0.0002) in whole brain, 4.8-fold (P6 0.0002) in hypothal-
amus, 3.3-fold (P6 0.0002) in liver and 1.8-fold (P6 0.001) in
small intestine of lean mice (Fig. 1). Leptin also increased
SOCS-3 mRNA by 1.9-fold (P6 0.001) in liver of ob/ob
mice compared with untreated ob/ob mice (Fig. 1). Paradoxi-
cally, SOCS-3 mRNA levels were increased by 3-fold
(P6 0.001) in whole brain, 2.5-fold (P6 0.004) in hypothal-
amus of ob/ob mice compared with same tissues of lean mice
(Fig. 1).
The cytokine-inducible gene CIS, distantly related to the
SOCS proteins, is a target of the JAK/STAT pathway and
has been shown to suppress tyrosine-phosphorylation of
STAT-5 and STAT-5 mediated transactivation in haemato-
poietic cells [24]. Following the 48 h leptin treatment in the
present study, CIS mRNA levels were increased by 9.3-fold
(P6 0.0001) in whole brain, 5.2-fold (P6 0.0001) in hypothal-
amus, 2.3-fold (P6 0.0002) in liver and 3.9-fold (P6 0.0001)
in small intestine of lean mice (Fig. 2). Furthermore, leptin
treatment increased CIS mRNA levels by 2.1-fold (P6 0.004)
in hypothalamus, 1.7-fold (P6 0.004) in liver and 1.4-fold
(P6 0.01) in small intestine of ob/ob mice compared with un-
treated ob/ob mice (Fig. 2). Similar to SOCS-3 mRNA levels,
CIS mRNA levels were paradoxically increased in whole brain
by 4.2-fold (P6 0.0002), 2-fold (P6 0.004) in hypothalamus
and 2.8-fold (P6 0.0002) in small intestine of ob/ob mice com-
pared with same tissues of lean mice (Fig. 2). Leptin treatment
had no e¡ect on CIS or SOCS-3 mRNA levels in WAT nor
did we detect any di¡erences in CIS or SOCS-3 mRNA levels
in WAT of ob/ob mice relative to the lean littermates (data not
shown).
To date, only SOCS-3 has been shown to be able to prevent
leptin-mediated signaling [14]. The ¢nding in the present study
that leptin induced CIS mRNA levels, led us to investigate
whether CIS was also a negative regulator of leptin signaling
in the leptin-responsive cell line RINm5F. Leptin (100 nM)
increased transcriptional activation from reporter plasmids
containing GAS (from the FcQRI promoter) and IRE (from
the human ICAM-1 promoter) STAT binding elements (Fig.
3A). Leptin-induced transcriptional activity was greater with
the IRE (which has a high a⁄nity for STAT-3) compared
with the GAS construct (which has a high a⁄nity for
Table 1
The e¡ect of sub-chronic leptin treatment on OB-R, STAT-3, STAT-5 and SOCS-2 mRNA levels in lean (+/?) and obese (ob/ob) mice
mRNA Whole brain Hypothalamus Liver Small intestine WAT
lean ob/ob lean ob/ob lean ob/ob lean ob/ob lean ob/ob
3 + 3 + 3 + 3 + 3 + 3 + 3 + 3 + 3 + 3 +
OB-R 1.9 1.7 2.5 2.2 0.9 0.8 1.8 1.6 1.8 1.5 1.8 2.0 2.4 2.6 2.7 2.4 0.4 0.5 0.4 0.6
STAT-3 0.4 0.5 0.5 0.5 0.7 0.8 0.6 0.7 0.8 0.6 0.7 0.6 0.4 0.3 0.4 0.4 0.5 0.5 0.6 0.5
STAT-5 0.7 0.6 0.6 0.6 0.9 1.2 1.1 1.0 1.4 1.2 1.6 1.5 1.6 1.8 1.7 1.6 0.7 0.6 0.7 0.8
SOCS-2 1.5 1.4 1.7 1.5 2.3 2.5 2.1 2.5 1.3 1.2 1.1 1.2 2.5 2.7 2.2 2.3 2.5 2.7 2.2 2.4
mRNA expression is relative to L-actin (arbitrary units) and results are expressed as mean of four independent experiments with S.E.M. of
þ 10^18%. Statistical signi¢cance was assessed using Student’s unpaired t-test. 2P6 0.04 and VP6 0.001 vs lean mice. Mice were treated with re-
combinant leptin (+) twice daily (2U1.5 mg/kg) for 2 days or with PBS without leptin (3).
Fig. 2. The e¡ect of 48 h leptin treatment (2U1.5 mg/kg i.p. twice
per day) on CIS mRNA levels in (a) whole brain, (b) hypothala-
mus, (c) liver and (d) small intestine. Results are expressed as
mean þ S.E.M. and statistical signi¢cance assessed using Student’s
unpaired t-test. **P6 0.002, ***P6 0.0002 vs 0 leptin, 2P6 0.004,
VP6 0.0006 vs lean mice. PCR products are displayed together with
the quantitation of CIS mRNA relative to L-actin.
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STAT-1) consistent with STAT-3 activation (Fig. 3A). CIS
was then co-transfected at di¡erent doses (2^8 Wg/transfection)
together with the IRE reporter plasmid (¢xed at 10 Wg) and
found to prevent leptin mediated transactivation of the IRE
promoter in a dose-dependent manner (see Fig. 3B). Thus in
addition to SOCS-3 as described previously [14], leptin indu-
ces CIS expression, which can subsequently suppress leptin
signaling.
Recently, Bjoerbaek et al. [14] demonstrated that acute (2
h) peripheral leptin administration (1^2 mg/kg, i.p.) induced
SOCS-3 mRNA expression in the ob/ob mouse hypothalamus,
whilst leptin had not e¡ect on the levels of SOCS-1, SOCS-2
or CIS mRNA. Furthermore, forced expression of SOCS-3,
but not CIS or SOCS-2, prevented leptin-mediated signal
transduction in CHO cells that were cotransfected with the
OB-Rb isoform [14]. In the present study, we ¢nd that a
similar dose of leptin administered for 48 h induced expres-
sion of both SOCS-3 and CIS in hypothalamus and peripheral
tissues. We also ¢nd that forced expression of CIS in clonal L-
cells that express the OB-Rb isoform prevented in a dose-
dependent fashion leptin-mediated STAT-3 transactivation.
It is possible that the di¡erence in the duration of the leptin
treatment, 2 h vs 48 h, as well as the di¡erence in the cellular
system used to study e¡ects of CIS on leptin signaling, could
explain the discrepancies between the present report and that
of Bjoerbaek et al. [14].
Cellular responses to cytokines are tightly controlled. An
essential step involved in this control is termination of the
cytokine signals. Multiple cytokines stimulate transcription
of the SOCS and CIS genes which encode Src-homology
(SH2) domains that can mask phosphotyrosine residues on
key molecules involved in the JAK/STAT signal transduction.
Thus CIS binds to phosphotyrosine residues of the L-chain of
interleukin 3 receptor as well as the erythropoietin receptor,
preventing activation of the STAT proteins [12]. This results
in the termination or dampening of the cytokine signal trans-
duction. Continuous expression of these suppressors could
render tissues unresponsive to cytokine action. Conversely,
inhibition of STAT activation would result in the reduction
of SOCS gene expression and a regain of responsiveness to the
particular cytokine. Loss of suppressors by other means, for
instance due to mutations in the SOCS and CIS genes, would
result in hyperresponsiveness that could contribute to the de-
velopment of a disease. We have found that 48 h leptin treat-
ment can lead to elevation of the SOCS-3 and CIS mRNA
levels in central and peripheral tissues. Moreover, both SOCS-
3 and CIS can prevent leptin signal transduction. This sug-
gests that leptin resistance is a consequence of obesity and
high leptin levels, although we cannot rule out the possibility
that in some individuals it may also be a cause.
We have also shown that SOCS-3 and CIS mRNA levels
are paradoxically increased in the hypothalamus of leptin de-
¢cient ob/ob mice relative to the lean controls. Since ob/ob
mice are sensitive to the e¡ects of leptin on feeding behaviour,
this di¡erence in SOCS-3 and CIS mRNA expression is appa-
rently inconsistent with the proposed role as suppressors of
leptin signaling. However there was also a two-fold increase in
OB-R in the ob/ob hypothalamus and this change could well
more than counteract the e¡ects of increases in cytokine sup-
pressors. Further, although leptin had less e¡ects on SOCS-3
and CIS mRNA levels in the ob/ob mouse, leptin treatment
caused a signi¢cant increase in CIS mRNA in hypothalamus
and some peripheral tissues of the ob/ob mouse suggesting
that these molecules have dampened the response to leptin
but not turned it o¡. Our results suggest that some tissues
in the ob/ob mouse might be less sensitive to leptin compared
with same tissues in the lean littermate. In fact, we have re-
cently found that SOCS-3 is increased in the pancreatic islets
of the ob/ob mouse relative to the lean littermate and this is
associated with reduced potency of leptin to inhibit stimulated
insulin secretion in ob/ob islets (unpublished results). Finally,
our results showing increased basal levels of SOCS-3 and CIS
in the leptin-de¢cient ob/ob mice suggest that factors other
than leptin, that are associated with obesity, can also induce
expression of these suppressors. In summary, we have dem-
onstrated that leptin treatment induces levels of the suppres-
sors of leptin signaling, SOCS-3 and CIS, in central and pe-
ripheral tissues of both lean and ob/ob mice which could be a
potential mechanism for leptin resistance.
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Fig. 3. Transcriptional activation of STAT-dependent reporter con-
structs by leptin and the e¡ect of forced expression of CIS in rat in-
sulinoma cells. A: RINm5F cells were transiently transfected with
STAT-dependent reporter plasmids pBLCAT2 (pBL; pBluescript) as
described in Section 2 and indicated below the axis. After a period
of serum starvation, the RINm5F cells were exposed to leptin (100
nM) for 12 h and then assessed for induction of CAT activity. No
induction was observed from the empty vector pBL (pBLCAT2). B:
Forced expression of CIS by the pSG5-CIS eucaryotic expression
vector in RINm5F cells, which was cotransfected (2^8 Wg pSG5-
CIS/transfection) with the IRE reporter plasmid (10 Wg), prevented
leptin-mediated transactivation.
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